Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 87,968 shares, a growth of 128.9% from the September 15th total of 38,427 shares. Based on an average daily volume of 5,958,426 shares, the days-to-cover ratio is currently 0.0 days. Currently, 10.2% of the company’s shares are sold short.
Analyst Ratings Changes
A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of Valion Bio, Inc. Common Stock to a “hold” rating in a research report on Saturday, September 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on Valion Bio, Inc. Common Stock
Valion Bio, Inc. Common Stock Stock Performance
Valion Bio, Inc. Common Stock Company Profile
Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc was incorporated in 2016 and is headquartered in Hayward, California.
See Also
- Five stocks we like better than Valion Bio, Inc. Common Stock
- Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?
- Failed Breakout in Tech? 3 Sectors Leading the Market Rotation
- Solaris Rides the AI Boom as Risks Mount
- Big Banks Report Strong Earnings—So Why Are Shares Falling?
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
